Comment on

• Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

  Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Kearns JT, et al. J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065. J Urol. 2019. PMID: 30076904 Free PMC article.